Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).
Colorcon will buy Indian group Pharmaceuitcal Coatings to expand both its tablet film coating business and presence in “rapidly growing” pharmaceutical market.
Germany’s Merck KGaA has completed its $7bn (€b5.2n) acquisition of Millipore, unveiling plans to target “high-growth, high-margin” bio-research and bio-production markets.
M&A can help revitalize firms but failure to properly integrate the companies can create an inefficient, demoralized business. In this article, Viq Pervaaz, senior vice president at Aon Consulting, takes a look at M&A processes, pitfalls and keys...
Merck & Co is to close or sell eight manufacturing plants and a further eight R&D laboratories as part of efforts to cuts its workforce by 15 per cent.
Rumour has it that French drug giant Sanofi Aventis is planning to make a $20bn (€16bn) acquisition in the US with speculation that biotechs like Allergan, Biogen Idec and Genzyme are among the targets.
Abbott Laboratories has confirmed it is considering the sale of the vaccines unit it gained with the €4.5bn ($6.2bn) acquisition of Solvay Pharmaceuticals in February.
India’s oldest pharmaceutical company Alembic went one step closer to the biggest restructuring in its history as its board approved the demerging of its main pharmaceutical business into a separate subsidiary company, Alembic Pharma.
Sosei has revealed its intention to acquire Activus Pharma in a deal which allows the Japan-based firm to get their hands on Activus' nanoparticle drug formulation tools, a technology that’s in its infancy but holds great potential.
A deal to broaden Gilead’s research expertise into protein kinase biology has been finalised with the $120m acquisition of CGI Pharmaceuticals, in a deal that compliments its comprehensive selection of anti-HIV treatments.
India-based Surya Pharmaceuticals is planning to raise Rs 500 crore ($100m) to fund construction of an active pharmaceutical ingredient (API) production plant, according to local media reports.
Adcock Ingram recorded an 11 per cent rise in profit in the first half of 2010 and is looking to continue this upwards trend through manufacturing expansions, plus local and overseas acquisitions.
Invida has acquired a stake in Indonesia-based MUGI, giving it the local manufacturing presence needed to offer partners access to “a vast untapped market”.
Pfizer plans to close eight manufacturing sites and reduce operations at a further six by the end of 2015, leading to 6,000 job losses, as part of its reorganisation after acquiring Wyeth.
DSM Biologics says combining its XD platform with newly-acquired Rhobust chromatography platform will create high yield, low cost bio-manufacturing option.
US drug packaging firm Comar says acquisition of Universal Container Corp (Unicon) provides capacity for growth, particularly in key liquid medication delivery device market.
Industrial glass maker Schott ended a “rather difficult” fiscal 2009 with a loss but says rise in drug packaging sales will help drive double-digit earnings growth in current financial year.
German pharmaceutical firm Merck KGaA says proposed Millipore acquisition will transform its chemicals unit and give it a more balanced business profile.
In a busy week of Big Phama results Pfizer reports sales boost from Wyeth, Roche says Genentech hit profits and GSK unveils surge in Relenza sales and plans to expand R&D restructuring.
Global packaging giant Amcor today announced that its acquisition of Alcan Packaging had been completed as it spelled out what the move would mean for suppliers and customers.
Blow-moulded packaging companies Pretium Packaging and Novapak Corporation have been taken over by New-York-based buyout firm Castle Harlan Inc in a deal worth $200m.
Pall says its acquisition of MicroReactor Technologies (MRT) broadens its offering in the $1bn (€689m) a year global biopharmaceutical process development market.
Daiichi-Sankyo subsidiary Luitpold Pharmaceuticals has acquired PharmaForce, giving it a 40,000 sq ft cGMP compliant sterile manufacturing facility and a 20,000 sq ft API production plant.
The US Department of Justice (DOJ) has given partial approval for Amcor’s takeover of Alcan after announcing it would now limit its review to Alcan’s Medical Flexible operations.
Ranbaxy Laboratories has sold its Chinese JV, Ranbaxy Guangzhou China Limited (RGCL), as part of a new approach to the country’s rapidly expanding drug market.
Ownership of FrieslandCampina Domo’s pharmaceutical lactose business will be transferred to DMV-Fonterra Excipients, the 50/50 JV set up by Domo owner Royal FrieslandCampina and partner Fonterra.
Novartis intends to acquire the remaining 75 per cent of Alcon for $39.3bn (€27.3bn), adding to the shares it bought in April 2008 and giving the big pharma control of the ophthalmic specialist.
Amcor’s takeover of Alcan has been cleared by the European Commission after the Australian company agreed to sell off two pharmaceutical and food packaging plants in Spain.
Amcor has unveiled its proposed management shake up in preparation for the $2.025bn takeover of Alcan – three days before the European Commission is due to deliver its verdict on the deal.
